Q-omics provides the consensus-scored RFX4 profile across patient tissues and cancer cell-line models. RFX4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RFX4 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, RFX4 RNA expression shows 14,937 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, THCA, and UVM as cancer lineages where RFX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFX4 survival associations across molecular data types. RFX4 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFX4 RNA expression–survival associations across cancer types. High RFX4 expression shows unfavorable associations in UCEC, KIRC, STAD, UVM and LGG, but favorable associations in KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for RFX4 RNA expression.
This table summarizes RFX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RFX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFX4 shows lower tumor expression in THCA, KICH, KIRC, LUAD and PRAD and higher tumor expression in COAD. The THCA box plot shows higher RFX4 RNA expression in normal versus tumor tissue (log2 FC = −0.314, t-test p < 0.001).
This table shows molecular features associated with RFX4 in patient tissues and cancer cell lines. In patient samples, RFX4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RFX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
